Chemotherapy remains a cornerstone of neoadjuvant immunotherapeutic strategies for TNBC; consequently, overexpression of ABC transporters can significantly diminish chemotherapeutic efficacy by reducing tumor cell death and subsequent antigen release, thereby impairing downstream immune activation. The gene discussed is ABCG2; the disease is neoplasm.